RAS SIGNALING AND LUNG CANCER

Lung cancer is the leading cause of cancer-related deaths both in Spain and worldwide. In addition, the 5-year-survival rate of less than 20Ͽas barely improved over the last decades. Approximately one quarter of these tumors are driven by mutations in KRAS, but so far no selective therapeutic strategy has been approved for these patients. Although inhibitors against a subset of KRAS oncoproteins have shown promising results in early phase trials, the majority of KRAS-mutant tumors will not benefit from these inhibitors. Moreover, resistance to these targeted therapies is a major concern.